Acta dermato-venereologica最新文献_第10页

How Adequately is the Severity of Atopic Dermatitis Assessed by Resident Physicians Training in Dermatology? Evaluation of the Intrarater and Interrater Reliability of Clinical Scoring Systems (EASI, oSCORAD, IGA, TIS Score, SASSAD). 皮肤科住院医师培训如何充分评估特应性皮炎的严重程度？临床评分系统（EASI, oSCORAD， IGA, TIS Score， SASSAD）的内部和内部可靠性评估。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2026-01-08 DOI: 10.2340/actadv.v106.43964

Katarzyna Waligóra-Dziwak, Katarzyna B Kubiak, Aleksandra Dańczak-Pazdrowska, Dorota Jenerowicz

{"title":"How Adequately is the Severity of Atopic Dermatitis Assessed by Resident Physicians Training in Dermatology? Evaluation of the Intrarater and Interrater Reliability of Clinical Scoring Systems (EASI, oSCORAD, IGA, TIS Score, SASSAD).","authors":"Katarzyna Waligóra-Dziwak, Katarzyna B Kubiak, Aleksandra Dańczak-Pazdrowska, Dorota Jenerowicz","doi":"10.2340/actadv.v106.43964","DOIUrl":"10.2340/actadv.v106.43964","url":null,"abstract":"Various scoring systems for atopic dermatitis assess different aspects of the disease, but the supporting data on their validation and reliability are often limited. To ensure accurate interpretations, it is essential to conduct thorough reliability and agreement testing. This study aimed to evaluate the reliability and reproducibility of 5 atopic dermatitis assessment tools - Eczema Area and Severity Index (EASI), objective Scoring Atopic Dermatitis Index (oSCORAD), validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD), Three Item Severity (TIS) score, and Six-Area, Six-Sign Atopic Dermatitis (SASSAD) severity score - among trained dermatology residents. Thirteen patients were assessed twice by 11 raters using each scoring system. Intrarater and interrater reliability were evaluated. EASI demonstrated the highest interrater reliability (ICC = 0.768 and 0.796); SASSAD and oSCORAD followed closely (ICC = 0.741 and 0.772; ICC = 0.723 and 0.709, respectively). The TIS (ICC=0.553 and 0.584) and IGA (Kendall's W=0.273 and 0.315) exhibited the lowest reliability. Given the generally higher reliability in this study compared with previous research, implementing standardized training on atopic dermatitis scoring systems early in the education of resident physicians may improve the reliability of these tools, equipping future dermatologists to perform effectively in clinical trials and drug programmes.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":"adv43964"},"PeriodicalIF":3.7,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12797255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145931815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous Lymphoma Associated with JAK Inhibitors: A Pharmacovigilance Analysis of the FAERS Database and Literature Review. 与JAK抑制剂相关的皮肤淋巴瘤：FAERS数据库的药物警戒分析和文献综述。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2026-01-08 DOI: 10.2340/actadv.v106.44546

Lu Lu, Jindi Feng, Huimin He, Yubin Peng, Shiyu Zhang, Lu Yang, Yuehua Liu, Tao Wang

{"title":"Cutaneous Lymphoma Associated with JAK Inhibitors: A Pharmacovigilance Analysis of the FAERS Database and Literature Review.","authors":"Lu Lu, Jindi Feng, Huimin He, Yubin Peng, Shiyu Zhang, Lu Yang, Yuehua Liu, Tao Wang","doi":"10.2340/actadv.v106.44546","DOIUrl":"10.2340/actadv.v106.44546","url":null,"abstract":"The increasing use of JAK inhibitors in clinical practice is raising concerns regarding the potential risk of cutaneous lymphoma. This study aimed to conduct a comprehensive search for cases of cutaneous lymphoma associated with JAK inhibitors in the Food and Drug Administration's Adverse Event Reporting System. The clinical characteristics of cases from January 2004 to September 2023 were retrieved from the FAERS database. Disproportionality and Bayesian analyses were performed to detect signals for cutaneous lymphoma associated with JAK inhibitors. In total, 24 cases of cutaneous lymphoma were identified associated with JAK inhibitors, including tofacitinib, ruxolitinib, baricitinib, upadacitinib, and abrocitinib. The majority of patients (64%) were aged 60 or older, with no significant difference in incidence between genders. The average onset time was 8.64 months. One patient with ruxolitinib experienced a fatal outcome, and 1 patient with tofacitinib had a life-threatening event. Cutaneous lymphoma associated with baricitinib has the highest reporting odds ratio (23.91, 95% confidence interval 10.71-53.4), proportional reporting ratio (23.88, χ2 = 103.67), information component (4.57, IC025 = 2.05), and empirical Bayes geometric mean (23.73, EBGM05 = 12.12). The occurrence of cutaneous lymphoma associated with JAK inhibitors highlights the importance of pharmacovigilance studies to deepen our understanding of both the medications and associated conditions.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":"adv44546"},"PeriodicalIF":3.7,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12797088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145931804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of Patient Satisfaction in Atopic Dermatitis. 特应性皮炎患者满意度的预测因素。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-22 DOI: 10.2340/actadv.v105.adv-2025-0096

Bruno Halioua, Charles Taieb, Stéphanie Merhand, Delphine Staumont-Salle

引用次数: 0

Paraneoplastic Pemphigus Mimicking Pemphigus Herpetiformis - Overlap of Two Diseases. 副肿瘤性天疱疮模拟疱疹样天疱疮-两种疾病的重叠。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-22 DOI: 10.2340/actadv.v105.adv-2025-0106

Sakura Maeda, Masahiro Tsutsumi, Kwesi Teye, Norito Ishii, Hiroshi Koga

引用次数: 0

Chronic Pruritic Annular Rash in a 47-year-old Man: A Quiz. 47岁男性慢性瘙痒性环状皮疹：一个小测验。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-18 DOI: 10.2340/actadv.v105.44722

Irene Unterman, Stephanie Benshushan, Karen Olshtain-Pops, Vered Molho-Pessach

引用次数: 0

Rapidly Progressing CD8-negative Hypopigmented Mycosis Fungoides in Adult Caucasian Male with Good Response to Mogamulizumab. 成年白人男性快速进展的cd8阴性低色素蕈样真菌病对莫加单抗反应良好。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-18 DOI: 10.2340/actadv.v105.43932

Agnieszka Kimak-Pielas, Taduesz Robak, Marcin Braun, Agnieszka Żebrowska, Ewa Robak

引用次数: 0

ENO1 Knockdown Impedes Tumour Progression and Promotes Oxidative Phosphorylation in Cutaneous Squamous Cell Carcinoma. en1敲低可阻碍皮肤鳞状细胞癌的肿瘤进展并促进氧化磷酸化。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-18 DOI: 10.2340/actadv.v105.43849

Liumei Song, Sharui Ma, Shengbang Wang, Xiu Zhang, Wenxin Fan, Ning Wang, Shuo Feng, Qiqi Duan, Ruimin Bai, Yan Zheng

{"title":"ENO1 Knockdown Impedes Tumour Progression and Promotes Oxidative Phosphorylation in Cutaneous Squamous Cell Carcinoma.","authors":"Liumei Song, Sharui Ma, Shengbang Wang, Xiu Zhang, Wenxin Fan, Ning Wang, Shuo Feng, Qiqi Duan, Ruimin Bai, Yan Zheng","doi":"10.2340/actadv.v105.43849","DOIUrl":"10.2340/actadv.v105.43849","url":null,"abstract":"Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy characterized by aggressive growth and metabolic reprogramming. Alpha-enolase (ENO1), a key glycolytic enzyme that is frequently over-expressed in cancer, has not been thoroughly investigated in cSCC, particularly with regard to how it coordinates glycolysis and oxidative phosphorylation (OXPHOS). ENO1 expression was interrogated in Gene Expression Omnibus datasets and validated in cSCC patient specimens. ENO1 was silenced in cSCC cell lines, and the resulting effects on cell viability, migration, invasion, apoptosis, and reactive oxygen species (ROS) levels were quantified. The impact of ENO1 knockdown on tumour growth was assessed in a xenograft model. Metabolic flux was analysed with Seahorse XFe96 extracellular-flux assays. ENO1 was significantly elevated in cSCC relative to normal skin and correlated positively with proliferative and invasive markers, but negatively with apoptosis markers. ENO1 silencing curtailed cell viability, migration, and invasion, while inducing apoptosis. Additionally, tumour growth was significantly impaired in vivo. Seahorse analysis showed that ENO1 knockdown suppressed glycolysis and redirected metabolic flux toward OXPHOS. Consistent with this shift, intracellular ROS increased and partially suppressed cell viability by modulating the ROS-sensitive Akt/mTOR pathway. In conclusion, ENO1 knockdown compromises tumorigenicity and promotes OXPHOS. Combining ENO1 inhibition with oxidative-stress-enhancing treatments, such as chemotherapy or radiotherapy, may further enhance efficacy.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43849"},"PeriodicalIF":3.7,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial. 阿布替尼治疗中重度特应性皮炎的疗效和安全性：一项非随机对照试验。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-16 DOI: 10.2340/actadv.v105.44200

Quanhong Zhang, Yue Zhu, Luoyao Yang, Yueping Zeng, Hongmei Zhang, Lang Yu, Gang Hu, Lei Hu, Liuqing Chen, Jinbo Chen

{"title":"Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial.","authors":"Quanhong Zhang, Yue Zhu, Luoyao Yang, Yueping Zeng, Hongmei Zhang, Lang Yu, Gang Hu, Lei Hu, Liuqing Chen, Jinbo Chen","doi":"10.2340/actadv.v105.44200","DOIUrl":"10.2340/actadv.v105.44200","url":null,"abstract":"There is a paucity of data regarding the use of Janus kinase inhibitors in elderly patients with moderate-to-severe atopic dermatitis necessitating systemic therapy. This study aimed to evaluate the efficacy and safety of abrocitinib compared with dupilumab in atopic dermatitis patients aged 60 years or older. A single-centre, non-randomized controlled trial (ChiCTR2300077724) was conducted from December 2022 to March 2024, in which 58 patients were assigned to receive either abrocitinib (100 mg daily) or dupilumab (600 mg loading dose followed by 300 mg every 2 weeks). The primary endpoints were the proportion of patients achieving a ≥ 4-point reduction in the Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 2 and the proportion achieving Eczema Area and Severity Index (EASI)-75 at Week 12; EASI-90 response at Week 24 was a key secondary endpoint. Results showed that a higher proportion of patients receiving abrocitinib achieved a PP-NRS4 response at Week 2 (52% vs 26%; p = 0.046). At Week 12, EASI-75 response rates were similar between the 2 groups (45% for abrocitinib vs 44% for dupilumab; p = 0.95). By Week 24, the EASI-90 response rate was 52% in the abrocitinib group compared with 41% in the dupilumab group (p = 0.4). Adverse events in the abrocitinib group included colon tumour (3%), nausea (6%), folliculitis (6%), and headache (16%), while the dupilumab group reported T-cell prolymphocytic leukaemia (3%) and conjunctivitis (7%). In conclusion, abrocitinib provided more rapid relief from pruritus and demonstrated superior long-term efficacy compared with dupilumab in the elderly population.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv44200"},"PeriodicalIF":3.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12730186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145766736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Treatment of Comorbid SAPHO Syndrome and Hidradenitis Suppurativa with Upadacitinib. Upadacitinib成功治疗SAPHO综合征和化脓性汗腺炎合并症。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-16 DOI: 10.2340/actadv.v105.44265

Deepika Narayanan, Tiffaney Tran, Valeria Duque-Clavijo, Hung Q Doan, Stephen K Tyring

引用次数: 0

Reduced Fibrinolysis Links Obesity to Cardiovascular Risk in Psoriasis Independently of Inflammation: A Novel Mechanistic Pathway. 减少纤维蛋白溶解将肥胖与银屑病心血管风险联系起来，独立于炎症：一个新的机制途径。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-12-16 DOI: 10.2340/actadv.v105.44720

Eva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Miodrag Janić

引用次数: 0